Novartis Halts Lu-NeoB Development After Early Clinical Data Fall Short
Novartis has discontinued the development of Lu-NeoB, an experimental cancer therapy designed to seek out tumor cells and deliver targeted radiation.
Search results for "Phase 2 clinical trial"
Lilly’s Retatrutide Cuts Weight by 22.6% in Phase 3 Trials, But Cardiovascular Protection Remains Unproven
Eli Lilly and Company’s next-generation obesity treatment, retatrutide, reduced body weight by up to 22.6% in Phase 3 clinical trials, though it did...
GSK Wins Early FDA Approval for Oral Lung Cancer Drug Jideytro Following $10.6 Billion Nuvalent Acquisition
A new oral therapy is now available for patients with ROS1-positive lung cancer whose disease has progressed following...
HLB Innovation Expands Phase 1 CAR-T Trial Following Clean Early Safety Data
HLB Innovation announced on July 23 that its U.S. subsidiary, Verismo Therapeutics, has expanded the Phase 1 clinical...
Novo Nordisk Secures EU Green Light for Oral Wegovy, Outpacing Eli Lilly in the Pill Market
The glucagon-like peptide-1 (GLP-1) obesity treatment market, long dominated by subcutaneous injections, is rapidly...
Celltrion Secures South Korean Phase 1 Approval for Tremfya Biosimilar CT-P68
Celltrion announced on July 15 that it has received approval from South Korea’s Ministry of Food and Drug Safety for an...
Daewoong’s Enblo Demonstrates Strong Potential to Reverse Fatty Liver in Diabetes Patients
Daewoong Pharmaceutical announced that its newly developed type 2 diabetes medication, Enblo (active ingredient:...
AI Trained on 200,000 Patient Records Predicts Early Mortality Risk in Severe Trauma
“Can we save this patient? Should we send them straight to the operating room, or does the intensive care unit come...
New Non-Invasive MRI Method Visualizes Elusive Liver and Intestinal Lymph Vessels
South Korean researchers have developed a breakthrough MRI technique that images the body’s lymphatic system without an...
United Therapeutics Acquires Thymmune, Betting 460 Billion Won on Thymus Cell Therapy
The race to develop regenerative cell therapies for an ultra-rare disease that leaves patients born without a...